Savara is actually a scientific-stage biopharmaceutical company building therapies for rare respiratory disorders. Its lead solution candidate is undoubtedly an immunostimulator called molgramostim. Molgramostim is in phase 3 scientific trials to treat autoimmune pulmonary alveolar proteinosis, or aPAP.This biography of the dwelling individual need